Inhibikase doses first subject in Phase IIa Parkinson’s treatment trial

Inhibikase Therapeutics has dosed the first subject in the Phase IIa 201 clinical trial of IkT-148009 to treat Parkinson’s disease.

The double-blind, randomised, 12-week dosing trial will analyse IkT-148009’s safety, tolerability, and steady-state pharmacokinetics as primary endpoints.